MAS825(抗IL1β和IL-18双特异性单克隆抗体)在全身型幼年特发性关节炎合并复发性巨噬细胞活化综合征两例患者中的长期疗效
本文报告两例伴有严重且难治性巨噬细胞活化综合征(MAS)及高血清IL-18水平的全身型幼年特发性关节炎(sJIA)患者,接受MAS825(抗IL1β和IL-18双特异性单克隆抗体)双靶点阻断后病情改善,并分别维持治疗18个月和10个月,显示可能的长期获益。
要点
- 两例sJIA患者均合并严重难治性MAS并伴高血清IL-18水平。
- MAS825双靶点阻断IL-1β和IL-18后,两例患者MAS参数均快速改善。
- 两例分别维持治疗18个月和10个月,病情控制良好。
核心结论
- 鉴于IL-1β和IL-18在sJIA、MAS和间质性肺病中的关键作用,MAS825可能是治疗耐药性sJIA的一种可能有效且安全的选择,尤其是在血清IL-18水平高的情况下。
研究设计与样本
- 本文为两例sJIA合并严重难治性MAS且高血清IL-18水平患者的病例报告,评估MAS825双靶点阻断IL-1β和IL-18的疗效。
主要发现
- 第一例为20岁男性,SARS-CoV-2感染后出现严重MAS并发血栓性微血管病,接受MAS825治疗后快速改善;18个月后仍每两周接受MAS825治疗,联合甲氨蝶呤、环孢素和低剂量糖皮质激素,疾病全身特征控制良好。
- 第二例为10岁女孩,耳部乳突炎后出现严重MAS并发可逆性后部脑病综合征,尽管接受静脉大剂量糖皮质激素、阿那白滞素和环孢素治疗,MAS仍未完全控制;开始每两周MAS825治疗后MAS参数迅速改善;10个月后继续接受MAS825并处于完全缓解。
临床怎么用
- 作者认为MAS825可能是治疗耐药性sJIA的一种可能有效且安全的选择,尤其在血清IL-18水平高的情况下。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic JIA (sJIA), a multifaceted autoinflammatory disorder, can be complicated by life-threatening conditions such as macrophage activation syndrome (MAS) and interstitial lung disease. The management of these conditions presents a therapeutic challenge, underscoring the need for innovative treatment approaches. OBJECTIVES: To report the possible role of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in the treatment of multi-drug-resistant sJIA. METHODS: We report two patients affected by sJIA with severe and refractory MAS and high serum IL-18 levels, responding to dual blockade of IL-1β and IL-18. RESULTS: The first patient is a 20-year-old man, presenting a severe MAS complicated by thrombotic microangiopathy, following SARS-CoV-2 infection. He was treated with MAS825, with quick improvement. Eighteen months later, the patient is still undergoing biweekly treatment with MAS825, associated with MTX, ciclosporin and low-dose glucocorticoids, maintaining good control over the systemic features of the disease. The second patient, a 10-year-old girl, presented a severe MAS case, complicated by posterior reversible encephalopathy syndrome, following an otomastoiditis. The MAS was not fully controlled despite treatment with i.v. high-dose glucocorticoids, anakinra and ciclosporin. She began biweekly MAS825, which led to a prompt amelioration of MAS parameters. After 10 months, the patient continues to receive MAS825 and is in complete remission. CONCLUSION: In light of the pivotal role of IL-1β and IL-18 in sJIA, MAS and interstitial lung disease, MAS825 might represent a possible valid and safe option in the treatment of drug-resistant sJIA, especially in the presence of high serum IL-18 levels.
引用
- Caorsi R, Bertoni A, Matucci-Cerinic C, et al. Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome. Rheumatology (Oxford). 2025. PMID: 39178016. doi:10.1093/rheumatology/keae440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。